Archive: 02/05/2016
Study shows how different people respond to aspirin—an important cardioprotective drug
Researchers have learned new information about how different people respond to aspirin, a globally prescribed drug in cardioprotection. The research team, led by scientists at Cardiff University in the United Kingdom and ...
May 2, 2016
Expand prescribing of buprenorphine for opioid abuse? Experts weigh pros and cons
Buprenorphine is a critical part of treatment for the growing epidemic of opioid abuse—but also carries the potential for misuse and diversion. The debate over whether 'to expand or not to expand' prescribing of buprenorphine ...
May 2, 2016
Umeclidinium for symptom relief in COPD: Added benefit not proven
Umeclidinium bromide (umeclidinium for short) has been approved since 2014 as a maintenance bronchodilator treatment in adults with chronic obstructive pulmonary disease (COPD) and was initially only available in combination ...
May 2, 2016
Mepolizumab in severe asthma: Added benefit not proven
The monoclonal antibody mepolizumab has been approved since the end of 2015 for the treatment of adults with severe refractory eosinophilic asthma. The German Institute for Quality and Efficiency in Health Care (IQWiG) now ...
May 2, 2016
Ibrutinib: Indication of added benefit in one of three therapeutic indications
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since ...
May 2, 2016
Novel electrode systems unveil the mechanisms behind human movement
For researchers in the fields of robotics and prosthetics, replicating the subtle combination of mechanisms underlying our movements is both an exciting and difficult challenge. Scientific efforts under the DEMOVE project ...
May 2, 2016